Celares GmbH
Home  |  Contact  |  Imprint
celares GmbH celares GmbH celares GmbH celares GmbH celares GmbH
 
 
 
 

Meet us at CPhI

Meet us at CPhI

October 7 - 9, 2014
Paris, France

Meet us at Bio USA

Meet us at Bio USA

June 23 - 26, San Diego, USA

New: Discrete 4-arm-PEG Maleimide

New: Discrete 4-arm-PEG Maleimide

The multimerisation with discrete 4-arm PEG facilitates defined linker lenght according to binding requirments

Hydrophilic linkers for ADCs

Hydrophilic linkers for ADCs

celares PEG based linker increase solubility of hydrophilic cytotoxic drugs

Welcome

Company

Company

Learn about our company and our motivation in more detail.

Products

Products

celares offers customized drug delivery solutions from development to production. Our products and services focus on improving the pharmacological properties of bi...

Technology

Technology

PEGylation is an established tool for increasing the tolerance, potency, half-life, and solubility of biopharmaceuticals. celares GmbH offers both propri...

Customized PEGylation Solutions

Biologics as therapeutics have gained substantial relevance during the past decades. Many of them are growth factors, interferons, enzymes, or antibodies and essentially contribute to the successful treatment of severe human diseases today. However, biologics routinely suffer from premature degradation by the patient defense system or renal excretion. The most established and best validated drug delivery strategy to overcome these problems is “PEGylation”, the modification of molecules with polyethylene glycol (PEG).

PEG is a water soluble and non-toxic molecule that significantly improves the pharmacological properties of biologics. Prominent examples are PEG-Intron®, Pegasys® or Neulasta® being block buster products in the market.

Due to its unique properties PEG is not only suitable for PEGylation. It is also an ideal reagent for the labeling or cross-linking of biologics, peptides or even small molecules. Furthermore, PEG-based linkers are perfectly suited for the production of antibody-drug conjugates (ADC). ADC is a new type of targeted therapy where cytotoxic drugs are

coupled to a scaffold protein, an antibody or antibody fragment with specific targets in disease associated tissues or cells. celares GmbH is a specialist for the delivery and enhancement of biologics with a proven track record in the development of PEGylated biologics, biosimilars, chemically modified drugs and ADCs, respectively. We provide customized solutions from development to production including reagents, development services and GMP products. Our clients will benefit from the comprehensive know-how in the successful development of chemically modified or PEGylated proteins and peptides.